MEI Pharma (NASDAQ:MEIP) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of MEI Pharma (NASDAQ:MEIP) in a research note issued to investors on Saturday morning. The brokerage issued a buy rating on the stock.

MEI Pharma Price Performance

MEIP stock opened at $2.87 on Friday. The company has a market capitalization of $19.12 million, a PE ratio of -0.41 and a beta of 0.78. MEI Pharma has a 12 month low of $2.30 and a 12 month high of $5.06. The firm’s 50-day moving average is $2.70 and its 200 day moving average is $2.92.

MEI Pharma (NASDAQ:MEIP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.20) earnings per share for the quarter. Sell-side analysts forecast that MEI Pharma will post -5.1 EPS for the current fiscal year.

Institutional Trading of MEI Pharma

An institutional investor recently bought a new position in MEI Pharma stock. Corsair Capital Management L.P. purchased a new stake in MEI Pharma, Inc. (NASDAQ:MEIP) during the third quarter, according to its most recent filing with the SEC. The firm purchased 24,370 shares of the company’s stock, valued at approximately $69,000. Corsair Capital Management L.P. owned 0.37% of MEI Pharma at the end of the most recent quarter. 52.38% of the stock is owned by institutional investors.

About MEI Pharma

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.